Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

853
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
853
Brain Imaging01:14

Brain Imaging

1.0K
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-Chelator conjugates for [<sup>68</sup>Ga]Ga- and [<sup>177</sup>Lu]Lu-based PSMA Radiotheranostics.

Bioorganic chemistry·2026
Same author

Development and Advantages of <i>O</i>-(Carboxymethyl)-<i>L</i>-tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer.

Journal of medicinal chemistry·2026
Same author

[<sup>68</sup>Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [<sup>68</sup>Ga]Ga-PSMA-11.

European journal of nuclear medicine and molecular imaging·2025
Same author

First-in-Human PET Imaging of Prostate Cancer Using [<sup>68</sup>Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [<sup>68</sup>Ga]Ga-AZ-NI-093.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Optimization of the radiosynthesis of the PSMA-targeting drugs [<sup>177</sup>Lu]Lu-P17-087 and [<sup>177</sup>Lu]Lu-P17-088 on the MiniLu™ automated module.

EJNMMI radiopharmacy and chemistry·2025
Same author

First-in-human study of a novel bifunctional PET tracer [<sup>68</sup>Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia.

European journal of nuclear medicine and molecular imaging·2025

Related Experiment Video

Updated: May 1, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

PET/SPECT imaging agents for neurodegenerative diseases.

Lin Zhu1, Karl Ploessl, Hank F Kung

  • 1Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China. zhulin111@gmail.com.

Chemical Society Reviews
|March 29, 2014
PubMed
Summary

Radioactive drugs for brain imaging, like those for Parkinson's Disease (PD) and Alzheimer's Disease (AD), aid diagnosis and drug development. Chemists are key to creating new imaging agents for neurodegenerative diseases.

More Related Videos

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
12:01

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke

Published on: June 14, 2018

13.5K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Related Experiment Videos

Last Updated: May 1, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
12:01

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke

Published on: June 14, 2018

13.5K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Area of Science:

  • * Nuclear medicine
  • * Medicinal chemistry
  • * Neurology

Background:

  • * Single photon emission computed tomography (SPECT) and positron emission computed tomography (PET) are crucial for diagnosing neurodegenerative diseases.
  • * Imaging agents, or radioactive drugs, significantly impact clinical diagnosis and patient care for conditions like Parkinson's Disease (PD) and Alzheimer's Disease (AD).

Purpose of the Study:

  • * To provide an overview of how SPECT and PET imaging agents are selected, prepared, and used in humans for neurodegenerative diseases.
  • * To highlight the role of brain imaging in understanding disease pathology and progression.
  • * To emphasize the utility of imaging in preclinical and clinical drug trials.

Main Methods:

  • * Review of selection criteria for neurodegenerative disease imaging agents.
  • * Description of chemical preparation methods for radioactive drugs.
  • * Discussion of human application and in vitro/in vivo assay testing.

Main Results:

  • * Imaging agents for PD and AD offer insights into disease mechanisms.
  • * Brain imaging provides valuable data on drug binding sites, facilitating clinical trials.
  • * Chemists play a vital role in developing novel imaging probes.

Conclusions:

  • * SPECT and PET imaging agents are indispensable tools in managing neurodegenerative diseases.
  • * The development of targeted imaging agents by chemists is essential for advancing diagnostics and therapeutics.
  • * Continued chemical innovation is critical for future breakthroughs in neurodegenerative disease research.